 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Infectious Diseases Fellow, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL
Professor of Pharmacy, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago
Reprints: Larry H Danziger PharmD, College of Pharmacy, University of Illinois at Chicago, Department of Pharmacy Practice (MC 886), 833 S. Wood St., Rm. 164, Chicago, IL 60612-7230, fax 312/413-1797, danziger{at}uic.edu
OBJECTIVE: To review and evaluate clinically relevant epidemiology, microbiology, and clinical studies regarding the treatment of multidrug-resistant Acinetobacter infections.
DATA SOURCES: Pertinent literature was identified by a MEDLINE search (1966–September 2003) and through secondary bibliographies of pertinent articles.
STUDY SELECTION AND DATA EXTRACTION: All English-language articles identified from data sources were evaluated for clinical relevance.
DATA SYNTHESIS: Acinetobacter baumannii has emerged as a worldwide problem as a nosocomial pathogen in hospitalized patients. Acinetobacter spp. can cause a multitude of infections including pneumonia, bacteremia, meningitis, urinary tract infections, and skin and soft tissue infections, and the mortality associated with these infections is high. Isolates resistant to almost all commercially available antimicrobials have been identified, thus limiting treatment options. The development of new agents and reappraisal of older compounds (ie, polymyxins, ampicillin/sulbactam) are necessary as we consider the optimal treatment of these multidrug-resistant organisms.
CONCLUSIONS: There is no simple answer to the treatment of Acinetobacter infections. Eradication of Acinetobacter spp. requires adherence to good infection control practices and prudent antibiotic use, as well as effective antimicrobial therapy. Alternative therapies such as colistin, ampicillin/sulbactam, and tetracycline are potential options, but prospective, randomized, controlled trials are still lacking.
Key Words: Acinetobacter baumannii, colistin, sulbactam
Published Online, July 27, 2004. www.theannals.com, DOI 10.1345/aph.1D592
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE
UNIVERSAL PROGRAM NUMBER: 407-000-04-026-H01
This article has been cited by other articles:
|
|
 |
|
  C. Dai, Y. Ma, Z. Zhao, R. Zhao, Q. Wang, Y. Wu, Z. Cao, and W. Li Mucroporin, the First Cationic Host Defense Peptide from the Venom of Lychas mucronatus Antimicrob. Agents Chemother., November 1, 2008; 52(11): 3967 - 3972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Russo, J. M. Beanan, R. Olson, U. MacDonald, N. R. Luke, S. R. Gill, and A. A. Campagnari Rat Pneumonia and Soft-Tissue Infection Models for the Study of Acinetobacter baumannii Biology Infect. Immun., August 1, 2008; 76(8): 3577 - 3586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rodriguez Guardado, A. Blanco, V. Asensi, F. Perez, J. C. Rial, V. Pintado, E. Bustillo, M. Lantero, E. Tenza, M. Alvarez, et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments J. Antimicrob. Chemother., April 1, 2008; 61(4): 908 - 913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Ko, J. Y. Suh, K. T. Kwon, S.-I. Jung, K.-H. Park, C. I. Kang, D. R. Chung, K. R. Peck, and J.-H. Song High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea J. Antimicrob. Chemother., November 1, 2007; 60(5): 1163 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Wexler Bacteroides: the Good, the Bad, and the Nitty-Gritty Clin. Microbiol. Rev., October 1, 2007; 20(4): 593 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Tan, J. Li, and R. L. Nation Activity of Colistin against Heteroresistant Acinetobacter baumannii and Emergence of Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3413 - 3415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Marchaim, S. Navon-Venezia, D. Schwartz, J. Tarabeia, I. Fefer, M. J. Schwaber, and Y. Carmeli Surveillance Cultures and Duration of Carriage of Multidrug-Resistant Acinetobacter baumannii J. Clin. Microbiol., May 1, 2007; 45(5): 1551 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Owen, J. Li, R. L. Nation, and D. Spelman In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates J. Antimicrob. Chemother., March 1, 2007; 59(3): 473 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Erridge, O. L. Moncayo-Nieto, R. Morgan, M. Young, and I. R. Poxton Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling J. Med. Microbiol., February 1, 2007; 56(2): 165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Hujer, A. M. Hujer, E. A. Hulten, S. Bajaksouzian, J. M. Adams, C. J. Donskey, D. J. Ecker, C. Massire, M. W. Eshoo, R. Sampath, et al. Analysis of Antibiotic Resistance Genes in Multidrug-Resistant Acinetobacter sp. Isolates from Military and Civilian Patients Treated at the Walter Reed Army Medical Center Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4114 - 4123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Falagas, P. K. Koletsi, and I. A. Bliziotis The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol., December 1, 2006; 55(Pt 12): 1619 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, C. R. Rayner, R. L. Nation, R. J. Owen, D. Spelman, K. E. Tan, and L. Liolios Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 2946 - 2950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Scheetz, K. M. Hurt, G. A. Noskin, and C. M. Oliphant Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. Am. J. Health Syst. Pharm., July 15, 2006; 63(14): 1346 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Rodriguez-Hernandez, J. Saugar, F. Docobo-Perez, B. G. de la Torre, M. E. Pachon-Ibanez, A. Garcia-Curiel, F. Fernandez-Cuenca, D. Andreu, L. Rivas, and J. Pachon Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii J. Antimicrob. Chemother., July 1, 2006; 58(1): 95 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Saugar, M. J. Rodriguez-Hernandez, B. G. de la Torre, M. E. Pachon-Ibanez, M. Fernandez-Reyes, D. Andreu, J. Pachon, and L. Rivas Activity of Cecropin A-Melittin Hybrid Peptides against Colistin-Resistant Clinical Strains of Acinetobacter baumannii: Molecular Basis for the Differential Mechanisms of Action. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1251 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Wareham, D. C. Bean, C. M. Urban, and J. J. Rahal In Vitro Activities of Polymyxin B, Imipenem, and Rifampin against Multidrug-Resistant Acinetobacter baumannii Antimicrob. Agents Chemother., February 1, 2006; 50(2): 825 - 826. [Full Text] [PDF]
|
|
|
|
|
|
A. Katragkou and E. Roilides Successful Treatment of Multidrug-Resistant Acinetobacter baumannii Central Nervous System Infections with Colistin J. Clin. Microbiol., September 1, 2005; 43(9): 4916 - 4917. [Full Text] [PDF]
|
|
|
|
|
|
L. Drago, E. De Vecchi, L. Nicola, L. Tocalli, and M. R. Gismondo In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with {beta}-lactams and amikacin J. Antimicrob. Chemother., August 1, 2005; 56(2): 353 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Turton, M. E. Kaufmann, J. Glover, J. M. Coelho, M. Warner, R. Pike, and T. L. Pitt Detection and Typing of Integrons in Epidemic Strains of Acinetobacter baumannii Found in the United Kingdom J. Clin. Microbiol., July 1, 2005; 43(7): 3074 - 3082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Poole Efflux-mediated antimicrobial resistance J. Antimicrob. Chemother., July 1, 2005; 56(1): 20 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Patel and C. W. Crank Gram-Negative Resistance in the Intensive Care Unit Journal of Pharmacy Practice, April 1, 2005; 18(2): 91 - 99. [Abstract] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
